“ The success of doxycycline is a major weapon in our new drug development strategy.” The company head said, “ The new drug took seven years to fill the gap in China.”
As a new generation of cyclic liposteroid antibiotics, doxycycline is regarded as another "milestone" in the field of antibiotics. Due to different antimicrobial mechanisms, doxycycline is much less likely to cause bacterial resistance than other antibiotics, and is currently the best treatment for gram-positive drug-resistant strains of infection. The introduction of domestic drugs will greatly reduce the cost of drugs for patients. At present, the only manufacturer of this product is American kubist Medicine Co.,Ltd., which was suspended from import in August this year for failing to pass the on-site inspection by China's drug administration, and Huadong Medicine products are faced with good market development opportunities after being approved for listing.
Anti-tumor, superantibiotic and cardiovascular and cerebrovascular medicine are three major fields in Huadong. In addition to the approval of the superantibiotic doxorubicin, a class of innovative drugs for lung cancer, myatinib, has been approved for clinical trials.
As one of the top ten listed pharmaceutical and medical companies in China and a leading enterprise in the pharmaceutical industry in the province, Huadong Medicine focuses on specialized drug use and has maintained steady double-digit growth for years. In the first three quarters of this year, the pharmaceutical industry of the company achieved operating revenue of 3.539 billion yuan, up 27.93% year-on-year, and realized net profit of 753 million yuan, up 45.51% year-on-year.
( The article appeared on the front page of Hangzhou daily on Nov 26, 2015)
width="35">
width="35">
Our Company
